Form 4 Filing for Doyle Mittie

On July 27, 2026, Doyle Mittie, Chief Medical Officer of Avalo Therapeutics, Inc., executed a series of transactions involving the company's Common Stock. Mittie acquired 1000 shares under a Rule 10b5-1 trading plan at a price of $12.65 per share, increasing their post-transaction holdings to 52,776 shares. Concurrently, Mittie disposed of 1000 shares at $20.00 per share, resulting in a post-transaction balance of 51,776 shares. Additionally, a stock option, representing the right to buy 1000 shares of Common Stock, was exercised. This option, with an exercise price of $12.65, was acquired under the same trading plan. The option vests in stages, with 25% vesting on July 15, 2025, and the remainder vesting monthly over the subsequent three years, contingent upon continued service. Following these transactions, the post-transaction number of shares owned is 124,750.